Compare IMRX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMRX | ORGO |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 348.6M |
| IPO Year | 2021 | 2016 |
| Metric | IMRX | ORGO |
|---|---|---|
| Price | $5.35 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $17.20 | $8.50 |
| AVG Volume (30 Days) | ★ 792.2K | 626.7K |
| Earning Date | 03-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.75 | ★ 1600.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | ★ N/A | $15.80 |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $1.10 | $2.26 |
| 52 Week High | $10.08 | $7.08 |
| Indicator | IMRX | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 29.21 |
| Support Level | $5.34 | $2.31 |
| Resistance Level | $5.36 | $4.12 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 79.07 | 28.45 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.